Top 10 Companies in the Nicorandil API Market (2026): Market Leaders Shaping Global Trends

The Global Nicorandil API Market was valued at USD 1.5 Billion in 2023 and is projected to reach USD 3.0 Billion by 2030, at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period. The influence of COVID‑19 and the Russia‑Ukraine War were considered while estimating market sizes.

As the cardiovascular drug market evolves, the spotlight is on the key API suppliers who are driving innovation, quality, and supply resilience. In this blog, we profile the Top 10 Companies in the Nicorandil API Market—a mix of established manufacturers and emerging players shaping the future of global cardiovascular therapeutics.

---

Nicorandil API Market – View in Detailed Research Report

The U.S. Market is estimated at USD 450 Million in 2023, while China is forecast to reach USD 950 Million by the same year. The Purity ≥ 99% segment is projected to reach USD 700 Million by 2030, with a CAGR of 6.5% over the next six years.

Nicorandil API is a vasodilator used primarily for angina pectoris and coronary artery disease. It combines nitrate and potassium channel opening properties, offering rapid symptom relief and improved myocardial perfusion. The API is typically formulated into tablets and injectable solutions, meeting stringent purity and stability requirements.

🔟 1. Tianfang Pharmaceutical

Headquarters: Tianjin, China
Key Offering: Nicorandil API (≥ 99% purity), bulk API for tablet and injection

Tianfang Pharmaceutical has positioned itself as a leading API supplier by investing heavily in process optimization and quality assurance. The company’s state‑of‑the‑art manufacturing facility in Tianjin incorporates continuous flow synthesis, reducing batch variability and accelerating time‑to‑market.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles, cutting solvent usage by 30%
• Expansion of the 99% purity line to meet rising demand for injectable formulations
• Strategic partnership with a European contract manufacturer to broaden global reach

9️⃣ 2. Yangzijiang Pharmaceutical Group – Jiangsu Haici Biological Pharmaceutical Co., Ltd.

Headquarters: Yangzhou, Jiangsu, China
Key Offering: Nicorandil API (≥ 99% purity), specialty API for advanced cardiovascular formulations

The group leverages its extensive R&D pipeline to refine synthesis routes, achieving higher yields and lower environmental impact. Its focus on specialty APIs aligns with the trend toward personalized medicine in cardiology.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop water system, reducing consumption by 25%
• Investment in renewable energy for its flagship plant
• Collaboration with academic institutions to explore novel delivery systems

8️⃣ 3. Xi’an Libang Pharmaceutical

Headquarters: Xi’an, Shaanxi, China
Key Offering: Nicorandil API (≥ 99% purity), bulk API for tablet and injection

Libang’s integrated production and logistics network allows it to respond swiftly to market fluctuations. The company’s emphasis on process scalability has enabled rapid expansion into emerging markets.

Sustainability & Growth Initiatives:

• Launch of a carbon‑neutral production line in 2025
• Development of a low‑toxicity synthesis route to minimize hazardous waste
• Partnership with a global distributor to increase market penetration in Southeast Asia

7️⃣ 4. Shanghai Xudong Haipu Pharmaceutical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Nicorandil API (≥ 99% purity), specialty API for injection

Haipu’s focus on high‑purity API caters to the premium segment of cardiovascular therapeutics. Its advanced purification technologies ensure consistent product quality, a critical factor for injectable formulations.

Sustainability & Growth Initiatives:

• Adoption of bio‑based solvents in synthesis processes
• Expansion of its injection line to meet growing demand in China and Hong Kong
• Collaboration with a leading biopharma company to co‑develop a next‑generation cardiovascular drug

6️⃣ 5. Nanjing Jinglun Pharmaceutical

Headquarters: Nanjing, Jiangsu, China
Key Offering: Nicorandil API (≥ 99% purity), bulk API for tablet and injection

Jinglun’s robust supply chain management and quality control systems have earned it a reputation for reliability. The company’s strategic sourcing of raw materials ensures price stability amid global supply disruptions.

Sustainability & Growth Initiatives:

• Implementation of a waste‑heat recovery system, cutting energy usage by 20%
• Development of a low‑cost synthesis route to improve margin in price‑sensitive markets
• Expansion into the Middle East through a joint venture with a regional partner

5️⃣ 6. China Resources Double Crane Pharmaceutical

Headquarters: Guangzhou, Guangdong, China
Key Offering: Nicorandil API (≥ 99% purity), specialty API for injection

Double Crane leverages its extensive distribution network to deliver APIs efficiently across China. Its focus on process innovation has driven consistent yield improvements.

Sustainability & Growth Initiatives:

• Investment in a state‑of‑the‑art purification plant using membrane technologies
• Initiatives to reduce greenhouse gas emissions by 15% by 2028
• Partnership with a European contract manufacturer to secure supply for EU markets

4️⃣ 7. Changchun Dazheng Pharmaceutical

Headquarters: Changchun, Jilin, China
Key Offering: Nicorandil API (≥ 99% purity), bulk API for tablet and injection

Dazheng’s emphasis on automation has streamlined production, reducing labor costs and enhancing throughput. The company’s compliance with international GMP standards positions it well for export opportunities.

Sustainability & Growth Initiatives:

• Adoption of an integrated waste‑management system, cutting waste volume by 30%
• Expansion of its 99% purity line to serve the growing demand for injectable APIs in Asia
• Collaboration with a global pharma company to co‑develop a cardiovascular combination therapy

3️⃣ 8. Mudanjiang Lingtai Pharmaceutical

Headquarters: Mudanjiang, Heilongjiang, China
Key Offering: Nicorandil API (≥ 99% purity), specialty API for injection

Lingtai’s focus on high‑purity API has enabled it to capture a niche segment of the market, particularly in the injectable space where purity thresholds are stringent.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop solvent recovery system
• Expansion of its injection line to meet demand in the Russian market
• Investment in research to develop a sustained‑release formulation of Nicorandil

2️⃣ 9. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Headquarters: Guangzhou, Guangdong, China
Key Offering: Nicorandil API (≥ 99% purity), bulk API for tablet and injection

Mingxing’s integrated R&D and manufacturing capabilities allow rapid prototyping and scale‑up of new API variants. The company’s focus on process efficiency has driven cost reductions.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for its manufacturing plants
• Implementation of a real‑time monitoring system for quality control
• Partnership with a leading contract manufacturer in the U.S. to expand global reach

1️⃣ 10. Jinzhou Jiutai Pharmaceutical

Headquarters: Jinzhou, Liaoning, China
Key Offering: Nicorandil API (≥ 99% purity), specialty API for injection

Jiutai’s emphasis on high‑purity API production has secured it contracts with several top-tier pharmaceutical companies. The company’s focus on continuous improvement has driven yield gains and reduced cycle times.

Sustainability & Growth Initiatives:

• Implementation of a zero‑liquid‑discharge system, eliminating wastewater
• Investment in a carbon‑capture unit to reduce CO₂ emissions
• Collaboration with a university research center to explore novel synthesis routes

---

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/269724/global-nicoril-api-forecast-market-2024-2030-573

---

Get Full Report Here: https://www.24chemicalresearch.com/reports/269724/global-nicoril-api-forecast-market-2024-2030-573

---

🌍 Outlook: The Future of Nicorandil API Is Driven by Quality and Supply Chain Resilience

The Nicorandil API market is undergoing a transformation. While traditional manufacturing remains dominant, the industry is investing heavily in process innovation, digital quality management, and green chemistry to meet tightening regulatory standards and rising demand for injectable formulations.

📈 Key Trends Shaping the Market:

• Shift toward continuous flow synthesis to improve yield and reduce batch variability
• Growing demand for high‑purity APIs in injectable cardiovascular products
• Increased focus on sustainability, including solvent recovery and renewable energy adoption
• Strategic partnerships between API manufacturers and global contract manufacturers to expand market reach

These developments position the market for a steady expansion, with a focus on quality, efficiency, and environmental stewardship.

---

📊 Future Trends Section

Emerging technologies such as artificial intelligence‑driven process control and advanced purification methods are set to redefine API production. Companies that invest in these areas will gain a competitive edge, enabling faster time‑to‑market and lower production costs.

Regulatory tightening around purity standards for injectable drugs will further incentivize the adoption of high‑purity production lines. The convergence of digital and green manufacturing will become a differentiator in the next decade.

For stakeholders looking to navigate this evolving landscape, a focus on process innovation, sustainability, and strategic alliances will be essential for long‑term success.